Researchers studying how antidepressants work in the brain have discovered a new pathway that can be manipulated to treat depression.
The pathway might offer a target to create more effective antidepressants.
“Identifying new pathways that can be targeted for drug design is an important step forward in improving the treatment of depressive disorders,” says Sarah Brooker, the first author of the study published in the journal Molecular Psychiatry and an MD/PhD student at Northwestern University Feinberg School of Medicine.
Brooker and colleagues found that drugs such as Prozac and tricyclics target a pathway in the hippocampus called the BMP signaling pathway. A signaling pathway is a group of molecules in a cell that work together to control one or more cell functions.
Like a cascade, after the first molecule in a pathway receives a signal, it activates another molecule and so forth until the cell function is carried out.
Their work shows that Prozac and tricyclics inhibit this pathway and, thereby, trigger stem cells in the brain to produce more neurons. These particular neurons are involved in mood and memory formation. But the scientists didn’t know if blocking the pathway contributed to the drugs’ antidepressant effect because Prozac acts on multiple mechanisms in the brain.
After confirming the importance of the BMP pathway in depression, the scientists tested a brain protein, Noggin, on depressed mice. Noggin is known block the BMP pathway and stimulate new neurons, called neurogenesis.
“We hypothesized it would have an antidepressant effect, but we weren’t sure,” Brooker says.
They discovered Noggin blocks the pathway more precisely and effectively than Prozac or tricyclics. It had a robust antidepressant effect in mice.
Scientists injected Noggin into the mice and observed the effect on mood by testing for depression and anxiety behavior. A sign of depression in mice is a tendency to hang hopelessly when held by the tail, rather than trying to get upright. After receiving Noggin, mice energetically tried to lift themselves up, whereas control mice were more likely to give up and become immobile.
The mice were then put in a maze with secluded (safe) and open (less safe) spaces. The Noggin mice were less anxious and explored more mazes than the control mice.
“The biochemical changes in the brain that lead to depression are not well understood, and many patients fail to respond to currently available drugs,” says Jack Kessler, a professor of neurology. “Our findings may not only help to understand the causes of depression, but also may provide a new biochemical target for developing more effective therapies.”
The National Institutes of Health funded the study.
Source: Northwestern University
The post Brain pathway could be new target for depression drugs appeared first on Futurity.